• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Weight Gain and Mood Stabilizers

Weight Gain and Mood Stabilizers

July 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD
While we have become sensitized to worrying about weight gain caused by antipsychotics, this side effect does occur with standard mood stabilizers as well. Recently, a comprehensive literature review was published evaluating the weight gain liabilities of medications commonly used to treat bipolar disorder (Torrent et al., Acta Psychiatrica Scand 2008;118:4-18). Here is what they found.

Lithium. Weight gain occurs in about 25% of patients, and ranges from 4.5 to 12 kg over the course of long-term treatment. Possible mechanisms: fluid retention, increased appetite, or lithium-related sub-clinical hypothyroidism. Polydipsia may also contribute to Li-induced weight gain, particularly if the patient drinks large quantities of high-caloric beverages.

Valproate. Weight gain occurs in 20-25% of patients, and ranges from 3-10 kg over 3-12 months, but one study reported a mean weight gain of 21 kg in 11 of 22 epileptic women over 7 years. VPA may cause polycystic ovarian syndrome in women, which may in turn contribute to weight gain.

Carbamazepine. CBZ has been shown to cause moderate weight gain in studies of epilepsy, but this has been less prominent in studies of bipolar disorder.

Gabapentin. One study of bipolar patients reported a mean weight gain of 0.9-3 kg after 12 weeks of treatment.

Lamotrigine. In many large studies, lamotrigine has been shown to produce no weight gain.
Typical antipsychotics. haloperidol, molindone, loxapine, and pimozide cause little or no weight gain in most patients.

Atypical antipsychotics.
Clozapine. Approximately 50% of patients gain at least 10-20% of body weight over several years of followup.

Olanzapine. In short-term trials, patients have gained 2-3 kg over 3-4 weeks of treatment, and about 4 kg after 10 weeks. In head-to-head comparisons, olanzapine causes more weight gain than valproate, risperidone, or ziprasidone.

Risperidone. Studies vary. One study reported a 2.5 kg gain over 3 weeks, while another showed only a 1.4 kg gain over 12 weeks.

Quetiapine. One study reported a 12 week weight gain of 2.6 kg. Another study showed no difference in weight gain between quetiapine and valproate.
Ziprasidone. Little if any weight gain.
Aripiprazole. Little if any weight gain.

Antidepressants. The following can cause significant weight gain: tricyclics, especially amitriptyline and imipramine, the MAOI phenelzine (less so tranylcypromine), paroxetine, and mirtazapine.
Looking for practical information on weight loss strategies for your patients?

The May 2005 issue of TCPR reviewed weight loss programs and medications, including xenical, subitramine, bupropion, and dexatrim.
General Psychiatry
KEYWORDS mood_stabilizers
www.thecarlatreport.com
Issue Date: July 1, 2008
SUBSCRIBE NOW
Table Of Contents
Antidepressants and Bipolar Disorder: An Update
Lamictal: What is it Good For?
Weight Gain and Mood Stabilizers
The Case in Favor of the Bipolar Spectrum
Is Bipolar Disorder Overdiagnosed?
SSRIs show weak advantage over bupropion for anxious depression
Computer as psychotherapist?
The History of Depakote
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.